Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc.（OCUL）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · OCUL · 截至 2026年6月8日
活动摘要
买入笔数
1
P-Purchase only
卖出笔数
29
近12个月
买卖比
0.03
Buy/Sell (by trades)
整体情绪
Ocular Therapeutix, Inc.内部人在过去近12个月主要在卖出股份，卖出行为通常由预设的Rule 10b5-1计划驱动，不一定代表对公司的负面看法。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月8日
OCUL 季度内部人买卖趋势
OCUL 内幕交易卖出 · OCUL 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 8, 2026
活跃内部人
近12个月交易最活跃 · OCUL CEO内幕交易
显示全部内部人 · 点击卡片过滤下方交易表
▸ 按reportingName聚合 · 近12月交易次数Top5 · 无额外API
近期内幕交易记录
OCUL 高管卖出股份 · OCUL 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Jun 3, 2026 | Waheed Nadia Chief Medical Officer | Sale | 14,828 | $123K | Form 4 |
| May 26, 2026 | Dugel Pravin See Remarks · Director | Sale | 21,156 | $173K | Form 4 |
| May 28, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| May 28, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| May 26, 2026 | Kaiser Peter Chief Development Officer | Sale | 2,967 | $24K | Form 4 |
| May 26, 2026 | Heier Jeffrey S. Chief Scientific Officer | Sale | 3,018 | $25K | Form 4 |
| May 26, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 1,858 | $15K | Form 4 |
| Apr 9, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| Apr 9, 2026 | Dugel Pravin See Remarks · Director | Gift | 394,696 | — | Form 4 |
| Feb 23, 2026 | Dugel Pravin See Remarks · Director | Sale | 20,056 | $166K | Form 4 |
| Feb 23, 2026 | Kaiser Peter Chief Development Officer | Sale | 2,810 | $23K | Form 4 |
| Feb 23, 2026 | Heier Jeffrey S. Chief Scientific Officer | Sale | 3,057 | $25K | Form 4 |
| Feb 23, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 1,759 | $15K | Form 4 |
| Feb 20, 2026 | Waheed Nadia Chief Medical Officer | Sale | 3,510 | $27K | Form 4 |
| Feb 20, 2026 | LINDSTROM RICHARD L MD Director | Purchase | 60,229 | $461K | Form 4 |
| Feb 12, 2026 | Notman Donald COO | Sale | 11,446 | $103K | Form 4 |
| Feb 12, 2026 | Nayak Sanjay Chief Strategy Officer | Sale | 10,348 | $94K | Form 4 |
| Feb 12, 2026 | Dugel Pravin See Remarks · Director | Sale | 124,882 | $1.13M⚡ | Form 4 |
| Feb 12, 2026 | Waheed Nadia Chief Medical Officer | Sale | 7,863 | $71K | Form 4 |
| Feb 2, 2026 | Notman Donald COO | Sale | 5,455 | $50K | Form 4 |
| Feb 4, 2026 | Notman Donald COO | Sale | 6,035 | $52K | Form 4 |
| Jan 21, 2026 | Robinson David Wayne Global CCO | Award | 136,000 | — | Form 4 |
| Jan 2, 2026 | Anderman Todd Chief Legal Officer | Award | 64,900 | — | Form 4 |
| Jan 2, 2026 | Meyers Steve Lawrence Chief Commercial Officer | Award | 64,900 | — | Form 4 |
| Jan 2, 2026 | Nayak Sanjay Chief Strategy Officer | Award | 64,900 | — | Form 4 |
⚡ = 金额≥$100万 · Award/Option价格显示— · 仅Form4 · 仅普通股
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 OCUL 内幕交易
OCUL 内幕交易
Ocular Therapeutix, Inc.（OCUL）内幕交易数据来源于公司内部人（包括Dugel Pravin (See Remarks · Director), Kaiser Peter (Chief Development Officer), Heier Jeffrey S. (Chief Scientific Officer)）提交的SEC Form 4申报文件。过去12个月内，5位内部人向SEC提交了交易申报。OCUL内部人近期主要在卖出，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Ocular Therapeutix, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
OCUL 内幕交易 · 5个问题Ocular Therapeutix, Inc.（OCUL）的内部人包括高管和董事，如Dugel Pravin (See Remarks · Director), Kaiser Peter (Chief Development Officer), Heier Jeffrey S. (Chief Scientific Officer)等。过去12个月内，5位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 8, 2026